RecombinantRabMAb

Recombinant Anti-PAR4 antibody [EPR3991] (ab92590)

Submit a review Submit a question References (1)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR3991] to PAR4
  • Suitable for: WB, IP
  • Reacts with: Mouse, Human

Overview

  • Product name

    Anti-PAR4 antibody [EPR3991]
    See all PAR4 primary antibodies

  • Description

    Rabbit monoclonal [EPR3991] to PAR4

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IPmore details
    Unsuitable for: Flow Cyt,ICC or IHC-P

  • Species reactivity

    Reacts with: Mouse, Human

  • Immunogen

    Synthetic peptide within Human PAR4 aa 1-100 (N terminal). The exact sequence is proprietary.

  • Positive control

    • LNCap, Jurkat, A549 and HeLa cell lysates

  • General notes

    Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab92590 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
IP
  • Application notes
    IP: 1/10 - 1/100.
    WB: 1/10000 - 1/50000. Predicted molecular weight: 37 kDa.

    Is unsuitable for Flow Cyt, ICC or IHC-P.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • Target

    • Function

      Pro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1.

    • Tissue specificity

      Widely expressed. Expression is elevated in various neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer, Parkinson and Huntington diseases and stroke. Down-regulated in several cancers.

    • Domain

      The leucine-zipper domain is not essential for apoptosis, but is required for sensitization of cells to exogenous apoptotic insults and for interaction with its partners.
      The SAC domain is a death-inducing domain selective for apoptosis induction in cancer cells. This domain is essential for nuclear entry, Fas activation, inhibition of NF-kappa-B activity and induction of apoptosis in cancer cells.

    • Post-translational
      modifications

      Preferentially phosphorylated at the Thr-163 by PKC in cancer cells.

    • Cellular localization

      Cytoplasm. Nucleus. Mainly cytoplasmic in absence of apoptosis signal and in normal cells. Nuclear in most cancer cell lines. Nuclear entry seems to be essential but not sufficient for apoptosis (By similarity). Nuclear localization includes nucleoplasm and PML nuclear bodies.
    • Information by UniProt

    • Database links

      • Alternative names

        • 2310001G03Rik antibody
        • PAR 4 antibody
        • PAR-4 antibody
        • Pawr antibody
        • PAWR_HUMAN antibody
        • PRKC Apoptosis WT1 Regulator antibody
        • PRKC apoptosis WT1 regulator protein antibody
        • Prostate apoptosis response 4 protein antibody
        • Prostate apoptosis response protein 4 antibody
        • prostate apoptosis response protein PAR-4 antibody
        • Transcriptional repressor Par-4-like protein PAWR antibody
        • Transcriptional repressor PAR4 antibody
        • WT1 Interacting Protein antibody
        see all

      Images

      • Western blot - Anti-PAR4 antibody [EPR3991] (ab92590)
        Western blot - Anti-PAR4 antibody [EPR3991] (ab92590)
        All lanes : Anti-PAR4 antibody [EPR3991] (ab92590) at 1/10000 dilution

        Lane 1 : LNCap cell lysate
        Lane 2 : Jurkat cell lysate
        Lane 3 : A549 cell lysate
        Lane 4 : HeLa cell lysate

        Lysates/proteins at 10 µg per lane.

        Secondary
        All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

        Predicted band size: 37 kDa

      • Immunoprecipitation - Anti-PAR4 antibody [EPR3991] (ab92590)
        Immunoprecipitation - Anti-PAR4 antibody [EPR3991] (ab92590)

        ab92590 at 1/40 immunoprecipitating PAR4 in Jurkat (human T cell leukemia T lymphocyte) whole cell lysate.

        Lane 1 (+): ab92590 + Jurkat whole cell lysate 

        Lane 2 (-): PBS instead of ab92590 in Jurkat whole cell lysate

        For western blotting, ab92590 was at 1/1000 dilution followed by Goat Anti-Rabbit IgG, (HRP), specific to the non-reduced form of IgG as the secondary antibody (1/1500). 

        Blocking buffer and concentration: 5% NFDM/TBST.

        Diluting buffer and concentration: 5% NFDM /TBST.

      • Anti-PAR4 antibody [EPR3991] (ab92590)
        Anti-PAR4 antibody [EPR3991] (ab92590)

      References (1)

      Publishing research using ab92590? Please let us know so that we can cite the reference in this datasheet.

      ab92590 has been referenced in 1 publication.

      • Lee SH  et al. Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature 561:127-131 (2018). PubMed: 30150773

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      There are currently no Customer reviews or Questions for ab92590.
      Please use the links above to contact us or submit feedback about this product.

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com